

**Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)**

Meeting – January 14, 2015 @ 4:00 p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call To Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. December 10, 2014 DUR Minutes – Vote
B. December 10, 2014 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**4. Update on Medication Coverage Authorization Unit/
Chronic Medication Adherence Program Update – See Appendix B**

- A. Medication Coverage Activity for December 2014
B. Pharmacy Help Desk Activity for December 2014
C. Chronic Medication Adherence Program Update

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**5. Action Item – Vote to Prior Authorize Duavee®
(Conjugated Estrogens/Bazedoxifene) – See Appendix C**

- A. College of Pharmacy Recommendations

Items to be presented by Dr. Anderson, Dr. Muchmore, Chairman:

**6. Action Item – Vote to Prior Authorize Natesto™ (Testosterone Nasal Gel), Avedo®
(Testosterone Undecanoate Injection), and Vogelxo™ (Testosterone Topical Gel) –
See Appendix D**

- A. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

**7. Action Item – Vote to Prior Authorize Ofev® (Nintedanib) and Esbriet® (Pirfenidone) –
See Appendix E**

- A. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

- 8. Action Item – Vote to Prior Authorize Anoro™ Ellipta® (Umeclidinium/Vilanterol), Incruse™ Ellipta® (Umeclidinium), Spiriva® Respimat® (Tiotropium), and Striverdi® Respimat® (Olodaterol) – See Appendix F**
A. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

- 9. 30-Day Notice to Prior Authorize Northera™ (Droxidopa) – See Appendix G**
A. Introduction
B. Northera™ (Droxidopa) Product Summary
C. College of Pharmacy Recommendations

Items to be presented by Dr. Anderson, Dr. Muchmore, Chairman:

- 10. Annual Review of Antiemetic Medications and 30-Day Notice to Prior Authorize Akynzeo® (Netupitant/Palonosetron) – See Appendix H**
A. Current Prior Authorization Criteria
B. Utilization of Antiemetic Medications
C. Prior Authorization of Antiemetic Medications
D. Market News and Updates
E. Akynzeo® (Netupitant/Palonosetron) Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of Antiemetic Medications: Fiscal Year 2014

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

- 11. 30-Day Notice to Prior Authorize Viekira Pak™ (Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir) – See Appendix I**
A. Introduction
B. Market News and Updates
C. Viekira Pak™ (Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir) Product Summary
D. Regimen Cost Comparison
E. College of Pharmacy Recommendations

Non-presentation, Questions Only:

- 12. Annual Review of Makena® (17-Hydroxyprogesterone Caproate) – See Appendix J**
A. Indication
B. Current Prior Authorization Criteria
C. Utilization of Makena® (17-Hydroxyprogesterone Caproate)
D. Prior Authorization of Makena® (17-Hydroxyprogesterone Caproate)
E. Market News and Updates
F. College of Pharmacy Recommendations

Non-presentation, Questions Only:

- 13. Annual Review of Gattex® (Teduglutide) – See Appendix K**
A. Indication
B. Current Prior Authorization Criteria
C. Utilization of Gattex® (Teduglutide)
D. Prior Authorization of Gattex® (Teduglutide)
E. Market News and Updates
F. College of Pharmacy Recommendations

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

14. FDA and DEA Updates – See Appendix L

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

15. Future Business

A. Annual Reviews

B. New Product Reviews

Items to be presented by Dr. Muchmore, Chairman:

16. Adjournment